Company news
Alterity Therapeutics Ltd. (ASX:ATH) news
Alterity Therapeutics Ltd. news releases on 6ix. Latest, Nov 18, 2019: Lead drug candidate receives positive opinion from EMA
Press releases — page 4
Lead drug candidate receives positive opinion from EMA
November 18, 2019
Appendix 4E & Annual Report 2019
August 30, 2019
Successful Completion of Phase 1 Clinical Trial
July 29, 2019
Alterity presents initial Phase 1 clinical trial data at AAN
May 6, 2019
Prana receives A$3.3 million R&D Tax Incentive Refund
March 18, 2019
Orphan Designation for PBT434 for treatment of MSA
January 30, 2019
Life Bioscience LLC leads strategic investment upto A$44.5M
December 27, 2018
New data show potential for PBT434 to treat MSA
October 5, 2018
Annual Report to shareholders
August 31, 2018
Prana to present PBT434 data at International Congress
July 8, 2018
First Volunteers Dosed in Phase I Clinical Trial of PBT434
July 3, 2018
Prana to commence Phase 1 clinical trial of PBT434
June 13, 2018
PBT434 at the 6th International Multiple System Atrophy Conf
March 6, 2018
Prana receives $3 million R&D Tax Incentive Refund
December 18, 2017
Prospectus Supplement
November 8, 2017
Notice of Meeting/ Proxy Form
October 13, 2017
Appendix 4E and Annual Report
August 31, 2017
Prana commences research collaboration with Takeda
July 18, 2017
PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
July 3, 2017
PBT434 presented at 13th International AD/PD Conference
March 30, 2017
Half Year Accounts
February 24, 2017
Business Update
December 23, 2016
S&P DJ Indices Announces March Quarterly Review
November 7, 2016
S&P DJ Indices Announces March Quarterly Rebalance
November 6, 2016
Prana provides regulatory update for PBT2
November 2, 2016
Prana announces $4.8 million R&D refund
October 30, 2016
New Reach2HD data presented at American Neurological Assoc.
October 18, 2016
Prana announces $6.5 million R&D refund
May 9, 2016
FDA Orphan Drug Designation for PBT2 for Huntington Disease
March 30, 2016
Appendix 4D Half Yearly Report and Accounts
February 25, 2016
Appendix 4E and Annual Report 2015
February 11, 2016
Safety Outcomes of Alzheimers IMAGINE Extension Trial
February 10, 2016